NCT00313287终止3 期
A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 mg QD in Patients Chronically Infected With Hepatitis B Virus
Bukwang Pharmaceutical63 个研究点 分布在 2 个国家目标入组 180 人开始时间: 2003年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 180
- 试验地点
- 63
- 主要终点
- Safety: clinically measured adverse events, abnormality of laboratory tests and abnormality of vital signs.
研究概览
简要总结
The purpose of this study is to determine safety and efficacy of 30 mg daily dose of clevudine (L-FMAU) at 24 weeks of treatment in patients with chronic HBV.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who were between 18 and 60, inclusive.
- •Patients with HBV DNA ³1 x 106 copies/mL within 30 days of baseline.
- •Patients who were documented to be HBsAg positive for > 6 months. (The documentation of positive HBsAg for the previous 6 months included previous laboratory reports of HBsAg positive or HBeAg positive at least 6 month ago or IgM anti-HBc negative and IgG anti-HBc positive at screening).
- •Patients who were HBeAg positive.
- •Patients with ALT levels which were in the range of ≥1.2 and < 15 times of the upper limit of normal (x ULN) and bilirubin levels less than 2.0 mg/dL, prothrombin time of less than 1.7 (INR), and a serum albumin level of at least 3.5 g/dL.
- •Women of child bearing potential with a negative serum (β-HCG) pregnancy test taken within 14 days of starting therapy.
- •Patients who were able to give written informed consent prior to study start and to comply with the study requirements.
排除标准
- •Patients who were currently receiving antiviral, immunomodulatory or corticosteroid therapy.
- •Patients previously treated with lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for HBV infection.
- •Previous treatment with interferon that had ended less than 6 months prior to the screening visit.
- •Patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy.
- •Patients co-infected with HCV, HDV or HIV.
- •Patients with clinical evidence of liver mass or with alpha-fetoprotein > 50 ng/mL
- •Patients who were pregnant or breast-feeding.
- •Patients who were unwilling to use an "effective" method of contraception during the treatment and for up to 3 months after cessation of therapy. For males, condoms should be used. Females had to be surgically sterile (via hysterectomy or bilateral tubal ligation) or post-menopausal or using at least medically acceptable barrier method of contraception ( i.e. IUD, barrier methods with spermicide or abstinence)
- •Patients with a clinically relevant history of abuse of alcohol or drugs.
- •Patients with a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, biliary diseases except asymptomatic GB stone, neurological, cardiovascular, oncologic or allergic disease.
- •The patients with a benign tumor were excluded if judged by an investigator that the continuation of study would be interfered by benign tumor.
- •Patients with creatinine clearance less than 60mL/min as estimated by the following formula :
- •(140-age in years) (body weight [kg]) (72) (serum creatinine [mg/dL]) [Note: multiply estimates by 0.85 for women]
- •Patients who were found to have YMDD HBV DNA polymerase mutation at baseline were to be excluded from the overall efficacy evaluation and analyzed separately. They were to be included in the overall safety evaluation.
结局指标
主要结局
Safety: clinically measured adverse events, abnormality of laboratory tests and abnormality of vital signs.
Efficacy:change from baseline in HBV DNA (log10) at Week 24
次要结局
- Efficacy:
- Proportion of patients with HBV DNA below the assay Limit of Detection
- Proportion of patients with HBeAg loss and/or seroconversion (HBeAg loss and HBeAb gain)
- Proportion of ALT normalization
研究者
研究点 (63)
Loading locations...
相似试验
终止
3 期
Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBVHepatitis BNCT00313274Bukwang Pharmaceutical80
已完成
2 期
The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19COVID-19NCT04891302Bukwang Pharmaceutical104
终止
2 期
Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B VirusHepatitis BNCT00305019Bukwang Pharmaceutical120
已完成
2 期
The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19COVID-19NCT04347915Bukwang Pharmaceutical64
已完成
3 期
Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB InfectionHepatitis BNCT00362635Bukwang Pharmaceutical92